Fastenal Company Announces Conference Call to Review 2025 Second Quarter Earnings
To access the call, please visit the following Web address:
https://investor.fastenal.com/events.cfm
Our conference call presentation (which includes information, supplemental to that contained in our earnings announcement, regarding results for the quarter) will be available at 6:00 a.m., central time, on the day of the conference call. To access the presentation, please visit the following Web address: https://investor.fastenal.com/releases.cfm
An online archive of the webcast will be available within one hour of the conclusion of the call and will remain available until September 1, 2025. Participants must have a compatible device with speakers to listen to the online webcast.
About Fastenal
With more than 3,500 in-market locations spanning 25 countries, Fastenal supplies a broad offering of fasteners, safety products, metal cutting products, and other industrial supplies to customers engaged in manufacturing, construction, warehousing, wholesale, and state and local government. By investing in local experts and inventory, customer-facing technology, wide-ranging services, and best-in-class sourcing and logistics, we offer a unique combination of capabilities to help our customers reduce cost, risk, and scalability constraints in their global supply chains. This "high-touch, high-tech" approach is reflected in our tagline, Where Industry Meets Innovation™.
Additional information regarding Fastenal is available on our website at www.fastenal.com.
FAST-G
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
IUX Deepens Commitment to African Market at Finance Magnates Africa Summit 2025
CAPETOWN, South Africa, July 02, 2025--(BUSINESS WIRE)--IUX made a notable impact at the Finance Magnates Africa Summit 2025 (FMAS:25) as a primary sponsor at the summit bar. The company not only stood out as a key participant but also created a dynamic atmosphere through its #DrinksOnIUX campaign. This initiative highlights IUX's commitment to expanding its presence and advancing digital trading solutions across the African region. Alex Delarue, Regional Commercial Director at IUX, shared, "Africa is one of the most dynamic regions for digital trading, and the energy at FMAS:25 reflected that. Our presence at FMAS:25 was about creating connections. We are committed to building long-term partnerships in Africa, and this summit was a powerful step forward in that journey. We were proud to show up boldly, connect authentically, and put IUX at the heart of the conversation." FMAS:25 served as a pivotal regional forum for leaders across the online trading, fintech, and payments industries. The IUX summit bar quickly became a prime gathering spot for attendees to refresh, exchange insights, and network. Through an interactive social media campaign, IUX fostered deeper connections and encouraged attendees to share memorable moments from the summit bar. IUX's involvement at FMAS:25 was a milestone in its continued growth across Africa, reinforcing the company's commitment to delivering secure and innovative digital trading solutions. The event also provided attendees with the opportunity to meet the IUX team and learn more about the company's offerings, while the online summit book further enriched their understanding of IUX's digital trading solutions. As the sponsor of the summit bar, IUX not only enhanced the event's atmosphere but also captured significant attention from attendees interested in learning more about its offerings. The #DrinksOnIUX campaign successfully engaged a wide audience, generating interest from potential clients and partners eager to stay updated on IUX's future developments. This engagement solidified IUX's position as a leading player in the African market, facilitating valuable connections for long-term growth. For more information on IUX, please visit View source version on Contacts Julia Kimjulia@ Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Barclays bullish on Kimco, Federal Realty as it launches coverage of retail REITs
-- Barclays starts coverage of retail REITs, rating Kimco Realty (NYSE:KIM) and Federal Realty Investment Trust (NYSE:FRT) Overweight while it was Equal weight on Regency Centers (NASDAQ:REG), Phillips Edison, Simon Property Group (NYSE:SPG) and Tanger. The brokerage said investors appear to be overpaying for the perceived defensiveness of certain grocery‑anchored portfolios, yet Kimco itself offers a cheaper way to own that theme. Barclays said New York‑based landlord is a large cap, high‑quality, diversified 'proxy' for grocery‑anchored shopping centers, trading at a modest discount to peers and set for about 5% funds‑from‑operations (FFO) growth next year. Federal Realty, whose high‑end shopping districts span U.S. coastal markets, has lagged rivals since the pandemic but is shifting capital toward lower‑risk acquisitions and more modest redevelopments, the note said. While Regency, Phillips Edison, Simon and Tanger all look fairly valued, the broker wrote. Regency carries a three‑turn premium to the sector on forward FFO, Phillips Edison still trades above peers despite shrinking returns on recent acquisitions, and both Simon and Tanger face apparel‑heavy tenant rosters that could be squeezed further if tariffs rise. Barclays' sector outlook favours companies with strong balance sheets and improving free‑cash‑flow profiles, and is wary of REITs chasing FFO growth through acquisitions after a sharp compression in shopping‑center cap rates. While consumer spending and tariff risks loom, Kimco and Federal Realty still screen as the best risk‑reward ideas in a retail landscape adjusting to slower economic growth. Investors, the bank cautioned, should remember that 'investors may be overpaying for the perceived defensiveness of certain grocery‑anchored portfolios.' Related articles Barclays bullish on Kimco, Federal Realty as it launches coverage of retail REITs Roblox: What's behind the meteoric rise of 'Grow a Garden' Quantum Computing started at Neutral on steep valuation, slow commercialization Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Good news for investors: You don't have to start out with tons of cash to grow wealth. Biotech stocks offer you a great opportunity to get in on innovators that may produce major growth down the road. 10 stocks we like better than Viking Therapeutics › Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You don't have to start out with a huge pile of cash to invest in stocks that may significantly add value to your portfolio over time. In fact, with just $200, you can get in on players that could help you along the path to wealth. The industry of biotech is a great place to look for such stocks since so many of these companies are developing cutting-edge technologies that may lead to high-growth products, and revenue, down the road. Let's consider two that you might buy today -- a few shares of each for a total of $200 -- and hold forever to benefit from lasting growth stories. Viking Therapeutics (NASDAQ: VKTX) aims to make its mark in one of today's (and tomorrow's) biggest healthcare growth areas: weight loss drugs. The biotech company is developing a dual GIP/GLP-1 receptor agonist, known as VK2735, and has progressed into late-stage clinical trials. The candidate, in injectable form, just launched its phase 3 program and aims to enroll more than 4,000 participants with obesity and more than 1,000 volunteers with obesity and type 2 diabetes. VK2735 works by interacting with hormonal pathways involved in the control of appetite and blood sugar levels, much like the already commercialized Mounjaro and Zepbound, sold by Eli Lilly, and Ozempic and Wegovy, sold by Novo Nordisk. But the fact that similar drugs have reached the market first doesn't mean Viking can't succeed here. Demand for these sorts of products has been so high that it exceeded supply, until Lilly and Novo Nordisk increased manufacturing capacity. So there's plenty of room for a young company like Viking to succeed here too if all continues to go well in clinical trials. Viking also is testing VK2735 in oral form in a phase 2 trial, an important point since oral formulation could make these drugs easier to take, and it involves faster and cheaper manufacturing processes for the company. Data from that trial is expected later this year. Viking stock is known to soar on positive results. It surged more than 120% last year in just one trading session after reporting positive phase 2 data for VK2735. It's since given up the gains, offering investors a solid entry point, but any good news and a possible regulatory nod could prompt the stock to skyrocket. Moderna (NASDAQ: MRNA) used to be a favorite of investors during the early days of the coronavirus pandemic -- but since, it's had trouble bringing investors back into its potential growth story. The stock has lost more than 90% since its peak back in 2021, and the company has reported decreasing sales because of the drop in demand for its coronavirus vaccine and lower-than-expected sales of its more recently launched respiratory syncytial virus (RSV) vaccine. After Moderna's billions of dollars in revenue and profit just a couple of years ago and recent earnings declines, investors may find it difficult to get excited about Moderna again. But it's important to remember two things: First, it's unfair to compare revenue potential during ordinary times to revenue linked to a pandemic-related product. Those were exceptional times that don't occur often. Second, the approval of Moderna's coronavirus and RSV vaccines show that its technology -- the technology driving the rest of its pipeline -- works. The company now has many late-stage products in the works and aims to launch as many as 10 over the next few years. If Moderna even makes it partially to that goal, its revenue picture a few years from now may look very different from the picture today -- and set the company up for long-term growth. It's too early to predict when the market will recognize this and flock to Moderna shares. But at today's level, the stock offers investors a buying opportunity, making it a great place to park part of your $200 and hold on for the long-term as this growth story develops. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna, Novo Nordisk, and Viking Therapeutics. The Motley Fool has a disclosure policy. Got $200? 2 Biotech Stocks to Buy and Hold Forever was originally published by The Motley Fool Sign in to access your portfolio
